Roots of Clinical Resistance to STI-571 Cancer Therapy
- 21 September 2001
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 293 (5538), 2163
- https://doi.org/10.1126/science.293.5538.2163a
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001
- Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.JNCI Journal of the National Cancer Institute, 2000
- Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.JNCI Journal of the National Cancer Institute, 2000
- Histone deacetylase inhibitors suppress IL-2–mediated gene expression prior to induction of apoptosisBlood, 2000
- Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceBlood, 2000
- Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell linesBlood, 2000
- Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationBlood, 2000
- Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic CellsMolecular and Cellular Biology, 1998